Q3 Earnings Forecast for CG Oncology Issued By HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – Equities researchers at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of CG Oncology in a research report issued on Thursday, August 6th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.96) for the quarter, down from their prior estimate of ($0.78). HC Wainwright currently has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($3.03) per share. HC Wainwright also issued estimates for CG Oncology’s Q4 2026 earnings at ($1.03) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($2.83) EPS and FY2028 earnings at ($0.65) EPS.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). The firm had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 26.58%.

CGON has been the topic of several other research reports. Wall Street Zen lowered shares of CG Oncology from a “sell” rating to a “strong sell” rating in a report on Saturday. Piper Sandler lifted their target price on shares of CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a research report on Friday. Wedbush upped their target price on shares of CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Truist Financial increased their price target on shares of CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday. Finally, JPMorgan Chase & Co. increased their price target on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $83.18.

CG Oncology Trading Up 1.9%

Shares of NASDAQ CGON opened at $76.56 on Monday. The firm has a market capitalization of $6.79 billion, a price-to-earnings ratio of -28.46 and a beta of 0.23. CG Oncology has a one year low of $23.65 and a one year high of $77.00. The business has a fifty day simple moving average of $67.47 and a 200 day simple moving average of $64.17.

Institutional Trading of CG Oncology

Several large investors have recently added to or reduced their stakes in CGON. Whittier Trust Co. of Nevada Inc. bought a new position in shares of CG Oncology in the fourth quarter valued at approximately $27,000. NFSG Corp bought a new stake in CG Oncology during the 1st quarter worth approximately $34,000. Comerica Bank grew its position in CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares during the last quarter. Fifth Third Bancorp bought a new stake in CG Oncology during the 1st quarter worth approximately $74,000. Finally, KBC Group NV acquired a new stake in CG Oncology during the 1st quarter valued at $78,000. 26.56% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Leonard E. Post sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total value of $350,000.00. Following the sale, the director owned 5,000 shares of the company’s stock, valued at approximately $350,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James Mulay sold 24,165 shares of the stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the sale, the director owned 24,165 shares of the company’s stock, valued at $1,816,241.40. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 37,129 shares of company stock worth $2,663,817 over the last three months. 4.80% of the stock is currently owned by corporate insiders.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.